Verici Dx plc

LSE VRCI.L

Verici Dx plc Cash and Short-Term Investments for the year ending December 31, 2023

Verici Dx plc Cash and Short-Term Investments is NA for the year ending December 31, 2023. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

LSE: VRCI.L

Verici Dx plc

CEO	Ms. Sara jane Barrington A.C.A., A.C.I.M.
IPO Date	Nov. 3, 2020
Location	United Kingdom
Headquarters	Avon House
Employees	19
Sector	Healthcare
Industries Biotechnology Clinical Trials Fintech

Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

Key trends

Past 5 years